Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 611 to 620 of 2608 total matches.

Expanded Table: Some Oral Drugs for Chronic Insomnia (online only)

   
The Medical Letter on Drugs and Therapeutics • Jan 09, 2023  (Issue 1667)
insomnia ...
View the Expanded Table: Some Oral Drugs for Chronic Insomnia
Med Lett Drugs Ther. 2023 Jan 9;65(1667):e6-10   doi:10.58347/tml.2023.1667b |  Show IntroductionHide Introduction

Desogestrel - A New Progestin for Oral Contraception

   
The Medical Letter on Drugs and Therapeutics • Aug 06, 1993  (Issue 902)
CONTRACEPTIVES 1 Estrogen (µg) µg per mg per Drug (ethinyl estradiol) month Progestin (mg) 2 month Cost 3 ...
Desogen (Organon) and Ortho-Cept (Ortho), two oral contraceptives each containing a low dose (30 mcg) of the estrogen ethinyl estradiol plus 150 mcg of the progestin desogestrel, were recently approved by the US Food and Drug Administration for marketing in the USA. They are the first US oral contraceptives to contain desogestrel, which is widely used in oral contraceptive combination products in other countries. Desogestrel is one of three new progestins (norgestimate and gestodene are the others) considered less androgenic than previously available progestins (L Speroff et al, Obstet...
Med Lett Drugs Ther. 1993 Aug 6;35(902):73-4 |  Show IntroductionHide Introduction

A New Testosterone Gel (Fortesta) for Hypogonadism

   
The Medical Letter on Drugs and Therapeutics • Apr 18, 2011  (Issue 1362)
as a Schedule III controlled substance. Table 1 lists some available testosterone products, including 2 ...
The FDA has approved Fortesta (Endo), a topical gel, for testosterone replacement therapy in adult males with hypogonadism. It is classified as a Schedule III controlled substance. Table 1 lists some available testosterone products, including 2 other gels.
Med Lett Drugs Ther. 2011 Apr 18;53(1362):29-30 |  Show IntroductionHide Introduction

Casirivimab and Imdevimab (REGEN-COV) for Post-Exposure Prophylaxis of COVID-19

   
The Medical Letter on Drugs and Therapeutics • Aug 23, 2021  (Issue 1631)
significantly less often in patients who received the antibodies than in those who received placebo (1.5% vs ...
The investigational monoclonal antibodies casirivimab and imdevimab (REGEN-COV – Regeneron) have been available in the US under an Emergency Use Authorization (EUA) since late 2020 for use together to treat mild to moderate COVID-19 in persons ≥12 years old who weigh ≥40 kg and are at high risk of progression to severe disease or hospitalization. The FDA has now expanded this EUA to allow use of the antibodies together for post-exposure prophylaxis of COVID-19 in such persons, if they are not fully vaccinated against COVID-19 or are unlikely to have an adequate immune response...
Med Lett Drugs Ther. 2021 Aug 23;63(1631):130-1 |  Show IntroductionHide Introduction

Tafenoquine (Arakoda; Krintafel) for Malaria

   
The Medical Letter on Drugs and Therapeutics • Jul 01, 2019  (Issue 1575)
: ta fen’ oh kwin Arakoda: air’ uh koh’ duh Krintafel: krin tah fell Table 1. Primaquine ...
The oral antimalarial tafenoquine succinate, a long-acting analog of primaquine, has been approved by the FDA in 2 different strengths. Arakoda (100-mg tablets; Sixty Degrees) is indicated for the prophylaxis of malaria in adults. Krintafel (150-mg tablets; GSK) is indicated for the prevention of relapse (radical cure) of Plasmodium vivax malaria in patients ≥16 years old undergoing treatment for acute P. vivax infection.
Med Lett Drugs Ther. 2019 Jul 1;61(1575):101-4 |  Show IntroductionHide Introduction

Treatment of Atrial Fibrillation

   
The Medical Letter on Drugs and Therapeutics • Jan 08, 2024  (Issue 1693)
.............................................................................. p 1 CHA2DS2-VASc Scoring ............................................................. p 2 Oral ...
Atrial fibrillation (AF) is the most common arrhythmia in the world. Risk factor modification, anticoagulation, rhythm control, and rate control are the four pillars of its management. American College of Cardiology/American Heart Association (ACC/AHA) guidelines on management of AF were updated recently.
Med Lett Drugs Ther. 2024 Jan 8;66(1693):1-8   doi:10.58347/tml.2024.1693a |  Show IntroductionHide Introduction

In Brief: Absorica for Acne

   
The Medical Letter on Drugs and Therapeutics • Jan 21, 2013  (Issue 1408)
available for treatment of acne.1 The FDA has recently approved a new oral isotretinoin product (Absorica ...
The oral retinoid isotretinoin (Accutane, and others) is the most effective drug available for treatment of acne.1 The FDA has recently approved a new oral isotretinoin product (Absorica – Cipher/Ranbaxy) for treatment of severe, recalcitrant nodular acne.Isotretinoin can completely clear severe nodulocystic lesions, in some cases leading to remission that can persist for years after treatment is stopped. Mucocutaneous adverse effects include dry skin, dry eye, epistaxis, nasopharyngitis, cheilitis, alopecia, eczema, skin fragility and photosensitivity. Musculoskeletal symptoms,...
Med Lett Drugs Ther. 2013 Jan 21;55(1408):8 |  Show IntroductionHide Introduction

In Brief: Neuropsychiatric Events with Montelukast

   
The Medical Letter on Drugs and Therapeutics • May 04, 2020  (Issue 1597)
of suicidal behavior and other serious neuropsychiatric events associated with its use.1 Montelukast ...
The FDA is requiring stronger warnings in the labeling of the leukotriene receptor antagonist montelukast (Singulair, and generics) about the risk of suicidal behavior and other serious neuropsychiatric events associated with its use.
Med Lett Drugs Ther. 2020 May 4;62(1597):65 |  Show IntroductionHide Introduction

Comparison Table: Some Topical Drugs for Rosacea (online only)

   
The Medical Letter on Drugs and Therapeutics • Feb 05, 2024  (Issue 1695)
in women Apply once/day 481.60/30 g 637.50/30 g Ivermectin – generic Soolantra (Galderma) 1% cream Yes ...
View the Comparison Table: Some Topical Drugs for Rosacea
Med Lett Drugs Ther. 2024 Feb 5;66(1695):e22   doi:10.58347/tml.2024.1695c |  Show IntroductionHide Introduction

Pramipexole and Ropinirole for Parkinson's Disease

   
The Medical Letter on Drugs and Therapeutics • Nov 21, 1997  (Issue 1014)
− Permax (Athena) 1.5 to 3 mg/d divided bid or tid 158.67 Pramipexole − Mirapex (Pharmacia & Upjohn) 0.5 ...
Pramipexole (Mirapex - Pharmacia & Upjohn) and ropinirole (Requip - SmithKline Beecham), two new dopamine agonists, have been approved by the US Food and Drug Administration (FDA) for treatment of both early (without levodopa) and advanced (with levodopa) Parkinson's disease. Bromocriptine (Parlodel) and pergolide (Permax) are older dopamine agonists marketed in the USA for adjunctive use with levodopa.
Med Lett Drugs Ther. 1997 Nov 21;39(1014):109-10 |  Show IntroductionHide Introduction